2021
Dietary Supplement Use and Interactions with Tamoxifen and Aromatase Inhibitors in Breast Cancer Survivors Enrolled in Lifestyle Interventions
Harrigan M, McGowan C, Hood A, Ferrucci LM, Nguyen T, Cartmel B, Li FY, Irwin ML, Sanft T. Dietary Supplement Use and Interactions with Tamoxifen and Aromatase Inhibitors in Breast Cancer Survivors Enrolled in Lifestyle Interventions. Nutrients 2021, 13: 3730. PMID: 34835986, PMCID: PMC8621720, DOI: 10.3390/nu13113730.Peer-Reviewed Original ResearchConceptsBreast cancer survivorsDietary supplement useCancer survivorsAromatase inhibitorsSupplement useDietary supplementsEndocrine therapyLifestyle interventionWorld Cancer Research Fund/American InstituteSelf-reported dietary supplement useNatural Medicines databaseAdjuvant endocrine therapyBreast cancer treatmentAdverse interactionsPotential adverse interactionsPharmacodynamic interactionsClinical efficacyCancer preventionHigh prevalenceGeneral populationPotential interactionsMedicine DatabaseTamoxifenCancer treatmentSurvivors
2012
Obesity and endometrial cancer survival: a systematic review
Arem H, Irwin M. Obesity and endometrial cancer survival: a systematic review. International Journal Of Obesity 2012, 37: 634-639. PMID: 22710929, PMCID: PMC3774112, DOI: 10.1038/ijo.2012.94.Peer-Reviewed Original ResearchConceptsEndometrial cancer survivorsDisease-specific mortalityEndometrial cancerCancer survivorsGeneral populationObesity-related mortalityProgression-free survivalEndometrial cancer survivalBody mass indexPopulation of womenHigh mortality rateMagnitude of associationMultivariate adjustmentHealthy womenMass indexProspective studyCancer survivalInclusion criteriaMEDLINE searchMortality rateObesitySystematic reviewSignificant associationMortalityMeSH keywords